Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

32.14 -3.28 (-9.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street ↗
Via The Motley Fool
News headline image
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy? ↗
Via The Motley Fool
News headline image
Is Novo Nordisk a No-Brainer Buy After It Dropped 40%? ↗
Via The Motley Fool
News headline image
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug. 
Via MarketBeat
News headline image
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped ↗
Ignore the noise in GLP-1 stocks. Find the best value instead. 
Via The Motley Fool
News headline image
Is Viking Therapeutics a Buy Right Now? ↗
Via The Motley Fool
News headline image
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled. ↗
The company will pay CordenPharma $150 million over three years in a manufacturing deal. 
Via Investor's Business Daily
News headline image
Is Eli Lilly Stock a Buy? ↗
Via The Motley Fool
News headline image
The State of Weight Loss Drugs ↗
Via The Motley Fool
News headline image
BJ's Wholesale Club Posts Better-Than-Expected Earnings, Joins Burlington Stores, Veeva Systems And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
2 Stocks to Buy With Less Than $40 ↗
Via The Motley Fool
News headline image
2 Stocks That Could Soar Again in 2025 ↗
Via The Motley Fool
News headline image
Has the Bubble Burst for Viking Therapeutics Stock? ↗
Via The Motley Fool
News headline image
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. ↗
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
News headline image
MarketBeat Week in Review – 02/24 - 02/28
Stocks tried to stage a weak rally to close the week but the short-term outlook will continue to be dictated by the uncertainty that is creating volatility 
Via MarketBeat
Topics Economy World Trade
News headline image
1 Biotech Stock to Buy in 2025, and 1 to Avoid ↗
Via The Motley Fool
News headline image
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. ↗
Via The Motley Fool
News headline image
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound. 
Via MarketBeat
News headline image
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk ↗
Via The Motley Fool
News headline image
Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today ↗
Via The Motley Fool
News headline image
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now ↗
Via The Motley Fool
News headline image
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip? ↗
Via The Motley Fool
News headline image
Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year ↗
In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity. 
Via Stocktwits
News headline image
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars ↗
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
News headline image
Market Movers: $ASTS Surges Again, $PBI Gears Up For Earnings! ↗
Pre-Market Briefing: Feb 6 – Top trade setups using our 4-pillar strategy! $ASTS leads the way, $PBI gears up for earnings, and $PTON & $APPS ride post-earnings momentum. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why. ↗
Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.